Pictet Asset Management (Switzerland)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$26.9M	Buy	582,976 +248,943	+75%	+$11.5M	0.03%	397
2023 Q1	$13.4M	Buy	334,033 +253,463	+315%	+$10.9M	0.02%	555
2022 Q4	$3.73M	Buy	80,570 +22,075	+38%	+$868K	0.01%	804
2022 Q3	$2.42M	Buy	58,495 +54,095	+1,229%	+$2.78M	﹤0.01%	892
2022 Q2	$263K	Hold	4,400	–	–	﹤0.01%	1328
2022 Q1	$320K	Hold	4,400	–	–	﹤0.01%	1330
2021 Q4	$370K	Hold	4,400	–	–	﹤0.01%	1303
2021 Q3	$397K	Buy	+4,400	New	+$398K	﹤0.01%	1295

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RARE Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Ultragenyx Pharmaceutical (RARE) stake by 75% in Q2 2023, buying an estimated $11.5M and bringing the position to 582,976 shares worth $26.9M. The position accounts for 0.03% of the portfolio, ranked #397.

Pictet Asset Management (Switzerland) first reported a position in RARE in Q3 2021 and has held it in 8 quarters since. 243 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

Pictet Asset Management (Switzerland) held 582,976 shares of Ultragenyx Pharmaceutical worth $26.9M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 248,943 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $11.5M.
Ultragenyx Pharmaceutical made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #397 holding.
Pictet Asset Management (Switzerland) first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and has held it in 8 quarters since.
243 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.